Advertisement

Topics

AstraZeneca Enters Respiratory Disease mRNA Collaboration with Ethris

10:21 EDT 21 Aug 2017 | Speciality Pharma Journal

MUNICH & GAITHERSBURG, Md.–(BUSINESS WIRE)–Ethris GmbH, a leader in mRNA-based therapeutics with specific expertise in pulmonary disease, today announced a five-year strategic research collaboration with AstraZeneca and its global biologics research and development arm, MedImmune. The collaboration is focused on developing new stabilised non-immunogenic modified RNA therapies for respiratory diseases using Ethris’ proprietary SNIM®RNA technology. …

Original Article: AstraZeneca Enters Respiratory Disease mRNA Collaboration with Ethris

NEXT ARTICLE

More From BioPortfolio on "AstraZeneca Enters Respiratory Disease mRNA Collaboration with Ethris"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Pulmonary
Pulmonary relating to or associated with the lungs eg Asthma, chronic bronchitis, emphysema, COPD, Cystic Fibrosis, Influenza,  Lung Cancer, Pneumonia, Pulmonary Arterial Hypertension, Sleep Disorders etc Follow and track Lung Cancer News ...

Biotechnology Business
Alliances Astrazeneca Bioethics Boehringer Clinical Research Organization Collaborations GSK Johnson & Johnson Lilly Merck Mergers and Acquisitions Nexium Novartis Pfizer Roche Sanofi ...

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...